Lee Rodne, CEO Admedus
Admedus (AHZ) is currently one of our high conviction stocks. We have an Add recommendation on the stock and a share price target of $A0.23.
Lee Rodne, CEO of Admedus, provides detail on the healthcare company and outlines key milestones due over the next three to six months. Interview by Morgans Senior Analyst Scott Power on 12 September 2014:
Morgans clients can access our detailed research on Admedus (AHZ). If you are interested in finding out more, please contact your nearest Morgans office.
Disclaimer(s): Morgans was Lead Manager to the SPP and Placement and earned fees in this regard.
The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.
Print this page